Nu-3, a Phase 2-ready candidate targeting the treatment of infected diabetic foot ulcers (iDFU), targets disruption of bacterial membranes through a unique, physical mechanism of action and has demonstrated...
Nu-3 is a gel formulation of a Bisphosphocin® compound targeting the topical treatment of infected diabetic foot ulcers with low likelihood of producing systemic side effects.
Company highlights its differentiated Bisphosphocin ® platform and lead clinical candidate Nu-3 as innovative approaches to addressing microbial infections and the risk of resistance development...
Leading clinician and surgeon to also serve as Scientific Advisor for Lakewood-Amedex Biotherapeutics' iDFU program
New patent enhances global IP footprint and pipeline expansion opportunities
SARASOTA, Fla. , June 16, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc. , (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent,...
Patent portfolio now includes 71 granted patents and 28 pending patent applications, covering composition of matter, formulation, and use patents
Key formulation, delivery and manufacturing steps completed in preparation for planned Phase 2 clinical trial
Specialized CRO partnership supports Phase 2 program to advance Nu-3 toward potential registration pathway in large, underserved iDFU market
Appointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listing